Table 2. Top five public-private partnerships by value. Three of the five largest public-private partnerships (PPPs) in 2011 are valued at $100 million or more. Listed PPPs do not include award and grant programs established by government institutes. Only 58 of the 247 PPPs reported in 2011 had disclosed dollar amounts. Excludes deals that only involved IP transfer.

Source: BioCentury Archives

Companies

Institutes

Business area

Disclosed value ($M)

Illumina Inc. (NASDAQ:ILMN)/
Roche (SIX:ROG; OTCQX:RHHBY)

New York Genome Center/11 U.S. institutes

Genomics

$125A

Gilead Sciences Inc. (NASDAQ:GILD)

Yale University

Cancer

$100

Pfizer Inc. (NYSE:PFE)

The Rockefeller University/New York University Langone Medical Center/Mount Sinai Medical Center/Columbia University Medical Center/Albert Einstein College of Medicine of Yeshiva University/Weill Cornell Medical College

Pharmaceuticals

$100

Advance BioChina

Institut Pasteur of Shanghai

Pharmaceuticals

$47.5-$95B

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

Cystic Fibrosis Foundation

Pulmonary disease

$75

A$100 million of $125 million has already been raised. BRange is calculated based on Advance BioChina disclosing that it would invest €1.5-€3 million ($1.9-$3.8 million) per company in up to 25 companies.